An investigation of the alpha1A-adrenergic receptor gene and antipsychotic-induced side-effects.
Antipsychotic treatment is hampered by the induction of side-effects such as tardive dyskinesia (TD), weight gain, sedation and extrapyramidal side-effects (EPS). Identification of the factors related to their development would facilitate their avoidance and the improvement of antipsychotic treatment. It has been hypothesised that genetic variants in drug targeted receptors may contribute to the development of side-effects. In this study, we have investigated the possible influence of genetic variants (-563-C/T, -4155-G/C and -4884-A/G) of the alpha(1A)-adrenergic receptor, an important target of atypical antipsychotic drugs, and development of side-effects after antipsychotic medication in a sample of N = 427 US Caucasian patients. We found several marginal associations (p < 0.05) between alpha(1A)-adrenergic genetic variants and antipsychotic-induced side-effects which did not reach statistical significance after corrections for multiple analyses. These results do not support a major role of alpha(1A)-adrenergic genetic variants in obesity and other side-effects observed after prolonged treatment with antipsychotic medications.
Saiz
Pilar A
PA
Clinical Neuropharmacology, Institute of Psychiatry-King's College, London, UK.
Susce
Margaret T
MT
Clark
Dan A
DA
Kerwin
Robert W
RW
Molero
Patricio
P
Arranz
Maria J
MJ
de Leon
Jose
J
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D003430:Cross-Sectional Studies; D004409:Dyskinesia, Drug-Induced / Q000209:etiology / Q000235:genetics; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000139:chemically induced; D020641:Polymorphism, Single Nucleotide; D018340:Receptors, Adrenergic, alpha-1 / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D044465:White People
C547713:ADRA1A protein, human; D014150:Antipsychotic Agents; D018340:Receptors, Adrenergic, alpha-1